In Pennsylvania, researchers are using genomic profiling to help future treatment of pancreatic cancer, which is the third leading cause of cancer deaths in the United States and has a low survival rate of 8%. One study found a mutation in the anaplastic lymphoma kinase gene and used targeted therapy for the mutated gene. Another study used existing medicines to improve pancreatic cancer outcomes with similar genetic mutations. The key was using the targeted genetic therapy early on as they found patients who had advanced too far with pancreatic cancer did not benefit as much as patients who were in the earlier stages.
Latest article
Dutch Queen promotes biobased building materials
In the Netherlands, Dutch Queen consort Máxima visited two Uden worksites promoting biobased building materials made from Netherlands fiber crops.
The March 26 visit...
ReefCircular launches crowdfunding campaign for shell bioconcrete
In Denmark, ReefCircular, a company developing a shell-based bioconcrete to help restore marine habitats, has launched a crowdfunding campaign on Kickstarter.
The company’s bioconcrete...
Aleph Farms raises $29 million for lab-grown steak
In Israel, cultivated meat producer Aleph Farms has raised $29 million to expand production at its Rehovot pilot plant and expand production into Europe...